AssetMark’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $15M | Sell |
71,193
-14,096
| -17% | -$2.83M | 0.03% | 465 |
|
|
2026
Q2 | $16.2M | Buy |
85,289
+8,579
| +11% | +$1.47M | 0.03% | 422 |
|
|
2026
Q1 | $13M | Buy |
76,710
+2,681
| +4% | +$458K | 0.03% | 442 |
|
|
2025
Q4 | $12.5M | Buy |
74,029
+73,980
| +150,980% | +$12M | 0.03% | 440 |
|
|
2025
Q3 | $7.07K | Buy |
49
+6
| +14% | +$819 | ﹤0.01% | 2232 |
|
|
2025
Q2 | $5.44K | Sell |
43
-63
| -59% | -$7.73K | ﹤0.01% | 2114 |
|
|
2025
Q1 | $13.6K | Sell |
106
-74
| -41% | -$10K | ﹤0.01% | 1783 |
|
|
2024
Q4 | $23.8K | Buy |
+180
| New | +$25.3K | ﹤0.01% | 1613 |
|
|
2022
Q4 | – | Sell |
-51
| Closed | -$6K | – | 1618 |
|
|
2022
Q3 | $6K | Buy |
51
+26
| +104% | +$3.23K | ﹤0.01% | 1274 |
|
|
2022
Q2 | $3K | Buy |
+25
| New | +$2.97K | ﹤0.01% | 1344 |
|
|
2021
Q2 | – | Sell |
-67
| Closed | -$10K | – | 1421 |
|
|
2021
Q1 | $10K | Buy |
67
+65
| +3,250% | +$10.3K | ﹤0.01% | 930 |
|
|
2020
Q4 | $0 | Sell |
2
-148
| -99% | -$21.2K | ﹤0.01% | 1430 |
|
|
2020
Q3 | $20K | Hold |
150
| – | – | ﹤0.01% | 835 |
|
|
2020
Q2 | $21K | Hold |
150
| – | – | ﹤0.01% | 790 |
|
|
2020
Q1 | $16K | Buy |
+150
| New | +$17.3K | ﹤0.01% | 911 |
|
|
2017
Q4 | – | Sell |
-21
| Closed | -$2K | – | 1987 |
|
|
2017
Q3 | $2K | Hold |
21
| – | – | ﹤0.01% | 1270 |
|
|
2017
Q2 | $2K | Hold |
21
| – | – | ﹤0.01% | 1222 |
|
|
2017
Q1 | $2K | Hold |
21
| – | – | ﹤0.01% | 1134 |
|
|
2016
Q4 | $2K | Hold |
21
| – | – | ﹤0.01% | 1135 |
|
|
2016
Q3 | $2K | Sell |
21
-147
| -88% | -$14K | ﹤0.01% | 1122 |
|
|
2016
Q2 | $14K | Sell |
168
-465
| -73% | -$41.7K | ﹤0.01% | 917 |
|
|
2016
Q1 | $55K | Sell |
633
-670,257
| -100% | -$59.9M | ﹤0.01% | 546 |
|
|
2015
Q4 | $75.7M | Sell |
670,890
-300,225
| -31% | -$32.6M | 1.4% | 18 |
|
|
2015
Q3 | $98.2M | Buy |
971,115
+440,313
| +83% | +$52.8M | 2.05% | 13 |
|
|
2015
Q2 | $65.3M | Sell |
530,802
-183,762
| -26% | -$22M | 1.36% | 22 |
|
|
2015
Q1 | $81.8M | Buy |
714,564
+316,104
| +79% | +$34.9M | 1.74% | 15 |
|
|
2014
Q4 | $40.3M | Buy |
+398,460
| New | +$38.7M | 0.88% | 34 |
|
|
2014
Q3 | – | Sell |
-23,748
| Closed | -$2.04M | – | 486 |
|
|
2014
Q2 | $2.04M | Buy |
+23,748
| New | +$1.87M | 0.04% | 200 |
|
Other funds holding IBB
AssetMark's IBB Position: Q3 2026 in Review
AssetMark reduced its iShares Biotechnology ETF (IBB) stake by 17% in Q3 2026, selling an estimated $2.83M and leaving 71,193 shares worth $15M. The position accounts for 0.03% of the portfolio, ranked #465.
AssetMark first reported a position in IBB in Q2 2014 and has held it in 28 quarters since. The position peaked at $98.2M in Q3 2015. 907 funds tracked by Wall St. Rank hold IBB as of Q3 2026.
- AssetMark held 71,193 shares of iShares Biotechnology ETF worth $15M as of Q3 2026.
- AssetMark sold 14,096 iShares Biotechnology ETF shares in Q3 2026, an estimated $2.83M.
- iShares Biotechnology ETF made up 0.03% of AssetMark's portfolio in Q3 2026, its #465 holding.
- AssetMark first reported a position in iShares Biotechnology ETF in Q2 2014 and has held it in 28 quarters since.
- AssetMark's iShares Biotechnology ETF position peaked at $98.2M in Q3 2015.
- 907 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.